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It was encouraging to read Hancock et al.’s economic analysis of detachable low dead 
space syringes (LDSS), which concluded that the syringes are cost saving and lead to 
additional quality adjusted life years (QALY) in relation to hepatitis C (HCV) transmission 
and disease progression.[1] This is a useful addition to the growing body of evidence 
indicating the acceptability of LDSS among people who inject drugs (PWID), although, as 
Hancock et al. acknowledge, further epidemiological evidence is needed to demonstrate 
their effectiveness in reducing HCV/HIV acquisition at a population level.[2-4]  
While the technological advances offered by LDSS are welcome, they are of limited use on 
their own. The provision of LDSS needs to occur alongside innovation within needle 
syringe programmes (NSP) to ensure unrestricted provision of injecting equipment and 
safe injecting advice reach underserved populations and those disengaged from services. 
LDSS must therefore be considered part of an integrated approach to alleviate social 
exclusion and reduce health inequalities faced by PWID.    
There is a critical need to avert the growing health crisis faced by PWID in the United 
Kingdom. The recent increase in HIV infections linked to injecting drug use in Glasgow, 
concentrated among those who were homeless or injecting cocaine, occurred in the 
context of on-going provision of NSPs.[5] This illustrates the inadequacy of wider services 
for those living in precarious circumstances, repeating lessons from Vancouver that 
showed HIV/HCV epidemics can thrive despite wide availability of NSPs.[6] 
Hospitalisations for serious bacterial infections and drug-related deaths have been 
steadily increasing since 2012, in line with cuts to health and social care services that 
have compounded vulnerabilities among PWID, particularly among the growing 
homeless population. [7-10] Unstably housed PWID face increased risk of HIV/HCV 
infection, poor mental health, respiratory diseases, bacterial infections and invasive and 
infectious diseases.[5,11,12] Hancock et al. employ a QALY measure as is standard within 
cost-effectiveness analysis in the UK. However, a narrow focus on health outcomes is 
insufficient when dealing with people experiencing complex interrelated health and 
social issues as it does not take into account aspects of social exclusion that affect well-
being.[13] Improving mental and physical health, reducing skin and soft tissue infections, 
and addressing social welfare needs must be equally prioritised. 
For the most marginalised PWID, access to NSP needs to be improved. Women who inject 
drugs are at increased risk of HIV/HCV acquisition, violence and poorer mental health 
compared to their male counterparts, but they also face barriers to services related to 
stigma, concerns about confidentiality, loss of child custody and gendered power 
imbalances in injecting relationships.[14-16] People who inject crack cocaine are also at 
increased risk of HIV and HCV acquisition and are less likely to use LDSS.[3,5,12] Services 
need to adapt to reach these underserved populations, distributing injecting equipment 
via secondary distribution, through peer-led outreach and in homeless hostels. This is 
imperative not only to increase provision of LDSS, but to establish contact and facilitate 
access to housing and other critical social and welfare support services.  
Hancock et al. model the impact of replacing high dead space syringes with LDSS 
distributed via the Bristol Drugs Project. This project is a very atypical service, as it is one 
of the last remaining fixed-site NSPs in the UK with a harm reduction focus, therefore 
limiting the generalisability of the study’s findings. It is important to work with other 
providers including pharmacies and mobile outreach to distribute LDSS and provide 
appropriate training to staff around safe injecting advice.[4,17] Future cost-effectiveness 
analyses will then need to consider these modalities.  
A key factor determining the relative health impact of LDSS is coverage; ensuring that 
PWID have sufficient supply of sterile equipment for each injection.[18] Recent data 
illustrate that often three or more attempts are necessary to obtain an injection among 
PWID.[19] The provision of multiple LDSS for each injection is needed to minimise risk 
of HCV, HIV, bacterial infections, venous damage and associated transitions to jugular and 
femoral injections. It is not clear what estimate of coverage is used in Hancock et al.’s 
analysis, but future analyses may need to revisit NSP coverage calculations to provide 
more accurate measures of cost-savings. Going forwards, it is essential to work with 
PWID to ensure that distribution of LDSS occurs through appropriate and diverse outlets 
with messaging that encourages the transition to LDSS by reflecting PWIDs’ priorities, 
such as emphasising LDSS benefits in reducing drug solution wastage over health 
benefits.[4] These interventions must be embedded within a broader strategy to tackle 
social exclusion among PWID in order to halt the increase in deaths and improve the 
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